Shuttle Pharmaceuticals Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $22.4M
- Price
- $4.71
- % Change (Daily % change from the live per-ticker quote feed.)
- +16.01%
- Volume
- 110.9K
About
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Quick stats
Shares outstanding4.8M
Computed float452.8K
Float / shares9.5%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001757499
AI Summary
AI-generated1/12
standardbearishlate filing
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Shuttle Pharmaceuticals received a Nasdaq noncompliance notice due to its failure to file the Form 10-Q for the quarter ended June 30, 2026.
The company has until October 27, 2026, to submit a plan to regain compliance, which could grant an extension period lasting until February 22, 2027.
While trading continues immediately, a non-compliance indicator will be added to the stock listing around September 4, 2026, with failure to regain compliance resulting in potential delisting.
Red flags
- Missed 10-Q filing deadline
- Received Nasdaq noncompliance notice
- Risk of delisting if compliance is not regained